Articles producció científica> Ciències Mèdiques Bàsiques

In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study

  • Dades identificatives

    Identificador: imarina:9267642
    Handle: https://hdl.handle.net/20.500.11797/imarina9267642
    Autors:
    Quindós GMiranda-Cadena KSan-Millán RBorroto-Esoda KCantón ELinares-Sicilia MJHamprecht AMontesinos ITortorano AMPrigitano AVidal-García MMarcos-Arias CGuridi ASanchez-Reus FMachuca-Bárcena JRodríguez-Iglesias MAMartín-Mazuelos ECastro-Méndez CLópez-Soria LRuiz-Gaitán AFernandez-Rivero MLorenzo DCapilla JRezusta APemán JGuarro JPereira JPais CRomeo OEzpeleta GJauregizar NAngulo DEraso E
    Resum:
    Background: Ibrexafungerp (SCY-078) is the newest oral and intravenous antifungal drug with broad activity, currently undergoing clinical trials for invasive candidiasis. Objective: The aim of this study was to assess the in vitro activity of ibrexafungerp and comparators against a collection of 434 European blood isolates of Candida. Methods: Ibrexafungerp, caspofungin, fluconazole, and micafungin minimum inhibitory concentrations (MICs) were collected from 12 European laboratories for 434 blood isolates, including 163 Candida albicans, 108 Candida parapsilosis, 60 Candida glabrata, 40 Candida tropicalis, 29 Candida krusei, 20 Candida orthopsilosis, 6 Candida guilliermondii, 2 Candida famata, 2 Candida lusitaniae, and 1 isolate each of Candida bracarensis, Candida catenulata, Candida dubliniensis, and Candida kefyr. MICs were determined by the EUCAST broth microdilution method, and isolates were classified according to recommended clinical breakpoints and epidemiological cutoffs. Additionally, 22 Candida auris from different clinical specimens were evaluated. Results: Ibrexafungerp MICs ranged from 0.016 to ≥8 mg/L. The lowest ibrexafungerp MICs were observed for C. albicans (geometric MIC 0.062 mg/L, MIC range 0.016–0.5 mg/L) and the highest ibrexafungerp MICs were observed for C. tropicalis (geometric MIC 0.517 mg/L, MIC range 0.06–≥8 mg/L). Modal MICs/MIC50s (mg/L) against Candida spp. were 0.125/0.06 for C. albicans, 0.5/0.5 for C. parapsilosis, 0.25/0.25 for C. glabrata, 0.5/0.5 for C. tropicalis, 1/1 for C. krusei, 4/2 for C. orthopsilosis, and 0.5/0.5 for C. auris. Ibrexafungerp showed activity against fluconazole- and echinocandin-resistant isolates. If adopting wild-type upper limits, a non-wild-type phenotype for ibrexafungerp was only observed for 16/434 (3.

  • Altres:

    Autor segons l'article: Quindós G; Miranda-Cadena K; San-Millán R; Borroto-Esoda K; Cantón E; Linares-Sicilia MJ; Hamprecht A; Montesinos I; Tortorano AM; Prigitano A; Vidal-García M; Marcos-Arias C; Guridi A; Sanchez-Reus F; Machuca-Bárcena J; Rodríguez-Iglesias MA; Martín-Mazuelos E; Castro-Méndez C; López-Soria L; Ruiz-Gaitán A; Fernandez-Rivero M; Lorenzo D; Capilla J; Rezusta A; Pemán J; Guarro J; Pereira J; Pais C; Romeo O; Ezpeleta G; Jauregizar N; Angulo D; Eraso E
    Departament: Ciències Mèdiques Bàsiques
    Autor/s de la URV: Capilla Luque, Javier / Guarro Artigas, Josep / LORENZO GUTIÉRREZ, DÀMARIS
    Paraules clau: Scy-078 Micafungin Ibrexafungerp Eucast Caspofungin Candida Antifungal testing Antifungal resistance
    Resum: Background: Ibrexafungerp (SCY-078) is the newest oral and intravenous antifungal drug with broad activity, currently undergoing clinical trials for invasive candidiasis. Objective: The aim of this study was to assess the in vitro activity of ibrexafungerp and comparators against a collection of 434 European blood isolates of Candida. Methods: Ibrexafungerp, caspofungin, fluconazole, and micafungin minimum inhibitory concentrations (MICs) were collected from 12 European laboratories for 434 blood isolates, including 163 Candida albicans, 108 Candida parapsilosis, 60 Candida glabrata, 40 Candida tropicalis, 29 Candida krusei, 20 Candida orthopsilosis, 6 Candida guilliermondii, 2 Candida famata, 2 Candida lusitaniae, and 1 isolate each of Candida bracarensis, Candida catenulata, Candida dubliniensis, and Candida kefyr. MICs were determined by the EUCAST broth microdilution method, and isolates were classified according to recommended clinical breakpoints and epidemiological cutoffs. Additionally, 22 Candida auris from different clinical specimens were evaluated. Results: Ibrexafungerp MICs ranged from 0.016 to ≥8 mg/L. The lowest ibrexafungerp MICs were observed for C. albicans (geometric MIC 0.062 mg/L, MIC range 0.016–0.5 mg/L) and the highest ibrexafungerp MICs were observed for C. tropicalis (geometric MIC 0.517 mg/L, MIC range 0.06–≥8 mg/L). Modal MICs/MIC50s (mg/L) against Candida spp. were 0.125/0.06 for C. albicans, 0.5/0.5 for C. parapsilosis, 0.25/0.25 for C. glabrata, 0.5/0.5 for C. tropicalis, 1/1 for C. krusei, 4/2 for C. orthopsilosis, and 0.5/0.5 for C. auris. Ibrexafungerp showed activity against fluconazole- and echinocandin-resistant isolates. If adopting wild-type upper limits, a non-wild-type phenotype for ibrexafungerp was only observed for 16/434 (3.7%) isolates: 11 (4.6%) C. parapsilosis, 4 (5%) C. glabrata, and 1 (2.5%) C. tropicalis. Conclusion: Ibrexafungerp showed a potent in vitro activity against Candida.
    Àrees temàtiques: Saúde coletiva Química Odontología Microbiology (medical) Microbiology Medicine (miscellaneous) Medicina veterinaria Medicina iii Medicina ii Medicina i Interdisciplinar Infectious diseases Immunology Geociências Farmacia Ensino Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Ciências agrárias i Biotecnología Biodiversidade
    Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
    Adreça de correu electrònic de l'autor: josep.guarro@urv.cat javier.capilla@urv.cat
    Identificador de l'autor: 0000-0002-7839-7568 0000-0002-0765-6403
    Data d'alta del registre: 2024-08-24
    Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
    Enllaç font original: https://www.frontiersin.org/articles/10.3389/fcimb.2022.906563/full
    URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
    Referència a l'article segons font original: Frontiers In Cellular And Infection Microbiology. 12
    Referència de l'ítem segons les normes APA: Quindós G; Miranda-Cadena K; San-Millán R; Borroto-Esoda K; Cantón E; Linares-Sicilia MJ; Hamprecht A; Montesinos I; Tortorano AM; Prigitano A; Vidal- (2022). In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study. Frontiers In Cellular And Infection Microbiology, 12(), -. DOI: 10.3389/fcimb.2022.906563
    DOI de l'article: 10.3389/fcimb.2022.906563
    Entitat: Universitat Rovira i Virgili
    Any de publicació de la revista: 2022
    Tipus de publicació: Journal Publications

  • Paraules clau:

    Immunology,Infectious Diseases,Medicine (Miscellaneous),Microbiology,Microbiology (Medical)
    Scy-078
    Micafungin
    Ibrexafungerp
    Eucast
    Caspofungin
    Candida
    Antifungal testing
    Antifungal resistance
    Saúde coletiva
    Química
    Odontología
    Microbiology (medical)
    Microbiology
    Medicine (miscellaneous)
    Medicina veterinaria
    Medicina iii
    Medicina ii
    Medicina i
    Interdisciplinar
    Infectious diseases
    Immunology
    Geociências
    Farmacia
    Ensino
    Ciências biológicas iii
    Ciências biológicas ii
    Ciências biológicas i
    Ciências agrárias i
    Biotecnología
    Biodiversidade

  • Documents:

    DocumentPrincipal

  • Cerca a google

    Search to google scholar